Season 2 (2021-2030)

Oncology - Gene Therapy (25)

Modality Indication Targets Stage Company Project No. Detail
1 Development of Lead compound of personalized therapeutic mRNA cancer vaccine by predicting the binding of tumor.reactive T cells and neoantigens
Gene Therapy Solid Tumor Tumor specific neoantigens predicted by a GENINUS platform based on binding affinity between TCR an Hit GENINUS INC. RS-2023-00284167
2 Development of universal iPSC.NK (induced pluripotent stem cellderived NK cell therapy) with higher ability of immune evasion and persistence for the treatment of solid cancer
Gene Therapy Liver cancer IL.15RF, HLA.G Candidate Therabest Co., Ltd RS-2023-00283732
3 Autologous 4th generation GPC3 CAR.T clinical study for advanced hepatocellular carcinoma
Gene Therapy Liver cancer GPC3 Phase 1 Eutilex Co.,Ltd. RS-2023-00283610
4 IL.21 on/off switch.armored solid tumor.targeting TET KO CAR.T cell therapy
Gene Therapy Solid Tumor IL.21 Hit Seoul National University RS-2023-00282907
5 Development of siRNA therapeutics to target KRAS/G12D.mutant pancreatic cancer
Gene Therapy Pancreatic cancer KRAS/G12D Candidate Exollence Co., Ltd. RS-2023-00282594
6 Development of HLA.G CAR.T cell therapy targeting HLA.G.positive solid tumors
Gene Therapy Solid tumor HLA.G Preclinical HK Inno. N RS-2023-00282541
7 TC011: Clinical Phase I Trial Evaluating Safety, Pharmacokinetics, DLT, MTD, Efficacy and RP2D of TC011, a CD19.Targeted CAR.T Therapyin Relapsed or Refractory B.Cell Non.Hodgkin Lymphoma Patients
Gene Therapy B cell lymphoma CD19 Phase 1 TICAROS RS-2023-00258721
8 Development of a gene therapy for ovarian cancer using bispecific shRNA and antibody escaping oncolytic adenovirus
Gene Therapy Ovarian cancer c-Myc, BCL2 Lead Curigin Co., Ltd. RS-2023-00219308
9 Non-clinical study of NRT-YHD-001 as macrophage immune check point blocker in liver cancer
Gene Therapy Liver cancer let-7i-5p miRNA Preclinical NEORNAT Inc. RS-2023-00217374
10 Development of first-in-class endoglin-targeted CAR-NK and its application for inducing immune-friendly microenvironment
Gene Therapy Relapsed and Refractory Pancreatic cancer Endoglin Lead Korea Institute of Science and Technology RS-2022-00166088
11 Secured ex vivo gene therapy candidate for the treatment of solid tumor
Gene Therapy Glioblastoma Cytosine Deaminase Candidate CELL & BRAIN Co., Ltd RS-2022-00165974
12 YYB-103
Gene Therapy Glioblastoma IL13Rα2 Phase 1 CellabMED HN22C0592
13 ARTI 101 : Oncospreading antitumor retroviral vectors
Gene Therapy Glioblastoma Cytosine Deaminase Candidate ArtiCure HN22C0469
14 Development of gene therapy for NMIBC using bispecific RNAi
Gene Therapy Bladder Cancer, Head And Neck Cancer, Pancreatic Cancer mTOR, STAT3 Preclinical Curigin HN22C0365
15 Development of personalized solid cancer therapy with neoantigen targeted TCR-T cells
Gene Therapy Solid Tumor Neoantigen Candidate Neogen TC HN22C0269
16 Preclinical Development of LEM-S403 Targeting Tumor Microenvironment Immune Modulation of Immune Checkpoint Inhibitor Non-Responsive Solid Tumor
Gene Therapy Solid Tumor IDO1 Preclinical Lemonex Inc. HN22C0262
17 Development of L1CAM targeted CAR-T therapy for recurrent ovarian cancer
Gene Therapy Ovarian Cancer L1CAM Preclinical Cartexell Inc HN22C0250
18 Phase I clinical study of innovative CD19-targeted CAR-T
Gene Therapy Non-Hodgkin Lymphoma CD19 Phase 1 AbClon Inc. HN22C0009
19 Development and optimization of a new form factor for next-generation cancer immunotherapy
Gene Therapy Solid Tumor DCs Hit Yonsei University HN21C1410
20 Development of candidate compounds for 
Probe & Catch CAR-T cells targeting 
CD40-positive hematologic tumors
Gene Therapy Blood tumor CD40 Candidate TiCARos Inc HN21C0764
21 Clinical trial and drug approval of the next generation CD19 CAR-T designed to overcome immune-suppressive environment
Gene Therapy Non-small cell lymphoma CD19 Phase 1 Curocell Inc. HN21C0653
22 Development of lead compounds for solid tumor-targeting CC12 platform-based reinforced B7H3 CAR-T cells
Gene Therapy Solid Tumor B7-H3, IL-12 Hit Seoul National University HN21C0232
23 Development of CAR T cell safety system using chemical switch
Gene Therapy Blood Cancer CAR-DEGRON-T Hit KRICT(Korea Research Institute of Chemical Technology) HN21C0226
24 Development and optimization of lead CD5 CAR-NK for T cell malignancies
Gene Therapy Blood Cancer CD5 Lead Korea Research Institute of Bioscience and Biotechnology HN21C0117
25 Establishment of leading compounds to overcome tumor heterogeneity and anticancer drug resistance of pancreatic cancer and liver cancer by using oncolytic adenovirus/mesenchymal stem cell complex capable of both enhanced tumor targeting and virus replication
Gene Therapy Pancreatic cancer, Liver cancer TGFβ1, HSP27 Lead Yonsei University HN21C0960
BACK